BRAF and colorectal carcinoma: CMS1 displays an immune system signature, along with marked B-Raf proto-oncogene and serine/threonine kinas (BRAF) mutations, while CMS2 is an epithelial-like type CRC (canonical type), characterized by c-Myc and Wnt signaling axis activation.